A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

October 31, 2015

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

PF804

45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)

Trial Locations (1)

120-752

Severance hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01608022 - A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus | Biotech Hunter | Biotech Hunter